Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2025)

vTv Therapeutics (VTVT) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.4 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 20.0% to -$0.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.17 through Dec 2025, up 5.65% year-over-year, with the annual reading at -$3.2 for FY2025, 0.0% changed from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.4 in Q4 2025 for vTv Therapeutics, up from -$1.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q2 2021 to a low of -$9.78 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.81 across 5 years, with a median of -$0.88 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 24123.62% in 2021 and later soared 82.92% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$8.19 in 2021, then decreased by 19.41% to -$9.78 in 2022, then skyrocketed by 82.92% to -$1.67 in 2023, then skyrocketed by 70.06% to -$0.5 in 2024, then grew by 20.0% to -$0.4 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VTVT at -$0.4 in Q4 2025, -$1.08 in Q3 2025, and -$0.92 in Q2 2025.